Managing local and global health risks

Preventative (primary) healthcare is action taken to stop people becoming ill in the first place, rather than treating them once they are sick.

It includes measures such as immunisation, clean water and sanitation, health education, good nutrition and antenatal care, which reduce the number of people who develop disease.

A vector is a living organism — often an insect such as a mosquito — that carries and transmits a pathogen from one host to another without causing the disease itself.

Vector control is the set of methods used to reduce or interrupt transmission by targeting the vector, for example insecticide-treated bed nets, indoor residual spraying and draining standing water where mosquitoes breed.

An example of a vector-borne disease is malaria, transmitted by the female Anopheles mosquito (dengue, spread by Aedes mosquitoes, is also acceptable).

Communicable (infectious) diseases are caused by pathogens (bacteria, viruses, parasites) that spread from person to person or via water, air, food or a vector. Examples include malaria, tuberculosis, cholera and HIV/AIDS.

Non-communicable diseases (NCDs) are not passed between people; they develop over time and are linked to genetics, ageing and lifestyle (diet, smoking, alcohol, inactivity). Examples include heart disease, cancer, stroke and type-2 diabetes.

In low-income countries, communicable diseases (together with maternal and child mortality) tend to dominate the disease burden, because of poverty, unsafe water, poor sanitation and weaker health systems.

As countries develop through the epidemiological transition, the burden shifts towards NCDs, which dominate in high-income countries.

The resource reveals an enormous gap in healthcare resources between the two development levels. The high-income country spends about US$4,800 per person** — roughly **120 times** the low-income country's **US$40 — and has 3.5 doctors per 1,000 people compared with only 0.2 (about 17 times more).

This suggests the high-income country can manage health risks through well-funded curative systems: many doctors, hospitals, screening programmes and long-term treatment for the non-communicable diseases that dominate at its level of development.

The low-income country, with almost no spending or doctors, cannot provide comprehensive curative care. It must rely on cheap, population-wide preventative measures (immunisation, clean water, bed nets) and on external help from aid and NGOs, and focuses on communicable disease and maternal/child health.

The data therefore show that development level strongly controls both the resources available and the type of management adopted — cure in the HIC, prevention and aid in the LIC. However, spending alone is not everything: a well-organised universal system (e.g. Cuba) can achieve good outcomes on modest resources, so how money is used also matters.

Immunisation reduces communicable disease by making people immune, so they cannot catch or transmit the pathogen. When a high enough proportion of a population is vaccinated, the disease can no longer spread (herd immunity), so cases fall and outbreaks die out.

The clearest example is the eradication of smallpox. Smallpox killed an estimated 300 million people in the 20th century, but a WHO-led global vaccination campaign — using ring vaccination (vaccinating everyone around each case) combined with surveillance and containment — drove cases down until the disease was declared eradicated in 1980. It remains the only human disease ever eradicated, showing how powerful coordinated immunisation can be.

The same approach is being used against polio: the Global Polio Eradication Initiative (launched 1988) has cut cases by over 99%, leaving the wild virus endemic in only a handful of countries (Afghanistan and Pakistan). Measles vaccination protects millions each year, though it needs ~95% coverage for herd immunity, and coverage gaps have allowed measles to re-emerge in some areas.

Immunisation is a cheap, preventative, population-wide tool that is especially valuable in LICs, delivered with support from the WHO and GAVI (the Vaccine Alliance). Its main limits are maintaining high coverage, reaching remote areas, and overcoming vaccine hesitancy.

Managing global health risks requires many players acting at different scales, because disease crosses borders and no single actor has all the resources or authority.

The WHO and IGOs are essential for coordination and equity (e.g. COVAX aimed to share COVID-19 vaccines with LICs), but the WHO cannot compel sovereign states and depends on member funding. National governments are the decisive players because they implement policy, yet their capacity varies hugely with development level — a strong HIC state versus a fragile LIC one. NGOs are flexible and reach the most vulnerable but are small-scale and reliant on donations. TNCs provide the scientific tools but need incentives or subsidies (e.g. advance market commitments) to serve poor markets.

In conclusion, effective management depends on these players working together: IGOs coordinate and fund, governments deliver, NGOs reach the excluded, and TNCs innovate. The biggest weakness is coordination and equity — when players pursue narrow national or commercial interests (vaccine nationalism), the poorest are left exposed, so partnership across scales is the key to managing global health risks.

Approaches to managing health risks range from preventative (immunisation, clean water, vector control) to curative (hospitals, drugs) and lifestyle interventions, and their effectiveness depends heavily on a country's level of development. This essay evaluates which approaches work best in low- and high-income contexts, arguing that effectiveness is context-dependent and that no single approach is universally best.

Managing health in low-income countries. LICs are dominated by communicable disease and maternal/child mortality, so the most effective approaches are cheap, preventative and population-wide. Immunisation has been transformative — the WHO-led eradication of smallpox (1980) and the near-eradication of polio (cases down over 99% since 1988) show prevention delivering huge gains at low cost. Vector control against malaria in sub-Saharan Africa — the scale-up of insecticide-treated nets (ITNs) funded by the Global Fund — helped cut malaria deaths substantially since 2000. These approaches are highly cost-effective and suit weak health systems, but they depend on external aid and NGOs (e.g. MSF), and progress can stall with funding gaps, incomplete coverage and insecticide/drug resistance. Curative care is limited by very low spending (as little as tens of dollars per person) and few doctors, so LICs cannot rely on treatment alone.

Managing health in high-income countries. Having controlled communicable disease, HICs face non-communicable diseases (NCDs) and manage them through well-funded curative systems and lifestyle interventions. HICs can afford advanced treatment — the USA spends ~17–18% of GDP on health — and screening, but this is expensive and treats disease late. Increasingly effective are preventative lifestyle policies: anti-smoking laws, sugar taxes (e.g. the UK Soft Drinks Industry Levy, 2018) and exercise campaigns tackle the causes of NCDs. So even in HICs, prevention is often more cost-effective than cure, though curative capacity is essential for an ageing population.

The role of the delivery model — not just wealth. How healthcare is organised matters as much as national income. Universal, tax-funded systems (the UK NHS; Cuba) give equitable access and strong primary care — Cuba achieves ~78-year life expectancy on modest resources, showing a well-run universal model can be highly effective. Insurance-based systems (USA) deliver high-quality care but leave coverage gaps, so access is uneven. In LICs, limited provision and out-of-pocket payment leave the poorest with the worst access. This shows that policy and organisation, not only development level, determine effectiveness.

Reaching a judgement. On balance, preventative approaches are the most effective and cost-effective at every development level, but the priorities differ: LICs gain most from immunisation, clean water and vector control (supported by international aid), while HICs need a combination of lifestyle prevention and well-funded curative care for NCDs. The most effective strategy is a blend matched to the disease profile, delivered through an equitable delivery model — Cuba's outcomes prove that organisation can outperform raw spending. The key weakness everywhere is sustaining funding and equity: approaches fail when money runs out or the poorest are excluded. Effectiveness is therefore context-dependent, and the best results come from combining prevention and cure appropriately for each level of development.

Managing health risks involves a spectrum from prevention (stopping disease occurring) to cure (treating it once it has), plus lifestyle interventions that sit between the two. This essay assesses how far prevention is more effective than cure, arguing that prevention is generally more cost-effective and equitable, but that cure remains indispensable and that the best strategy combines both, matched to development level.

The case that prevention is more effective. Prevention tackles disease before it causes harm, so it is usually cheaper per life saved and reaches whole populations. The most striking evidence is the eradication of smallpox (WHO, 1980) — a disease that killed ~300 million people in the 20th century was removed entirely by vaccination, something no amount of curative treatment could achieve. Polio is following the same path (cases down over 99% since 1988). In LICs, preventative vector control against malaria — the scale-up of insecticide-treated nets in sub-Saharan Africa, funded by the Global Fund — cut deaths far more cheaply than treating each case. Even in HICs, prevention is winning ground: lifestyle interventions such as anti-smoking laws and the UK sugar tax (2018) reduce NCDs at their source, far cheaper than treating heart disease or diabetes later. Prevention is also more equitable, because population-wide measures (clean water, immunisation) reach the poor who cannot afford treatment.

The case that cure is still essential. Prevention cannot do everything. Not all disease is preventable — many NCDs (cancers, genetic conditions) and injuries require curative treatment, and ageing HIC populations depend on hospitals, surgery and long-term drugs. Prevention also fails or is incomplete: vaccines need high coverage (measles has re-emerged where coverage fell), and when prevention breaks down, curative capacity saves lives — antimalarial ACT drugs treat those who still catch malaria, and antiretrovirals turn HIV into a manageable condition. During pandemics, when a pathogen is new and no vaccine yet exists (early COVID-19), curative and supportive hospital care is the only defence. A country with strong prevention but no curative system would be dangerously exposed.

The role of development level and delivery model. Effectiveness depends on context. LICs get the best value from prevention because curative care is unaffordable (spending can be tens of dollars per person, with ~0.2 doctors per 1,000), and they rely on aid and NGOs. HICs can afford both and need curative systems for NCDs as well as lifestyle prevention. The delivery model matters too: universal systems (NHS, Cuba) integrate prevention and cure equitably — Cuba's strong primary/preventative care achieves ~78-year life expectancy on modest spending — while insurance systems (USA) spend heavily on cure yet leave coverage gaps. This shows prevention and cure are complements, not alternatives.

Assessment and conclusion. On the extent of the claim, I largely agree that prevention is more effective — it is cheaper, population-wide, more equitable and can eradicate disease (smallpox), which cure never can, and it suits the LIC contexts where most of the global disease burden lies. However, the claim is too absolute. Cure is essential for the unpreventable, for treatment failures and for new pandemics, and HIC ageing populations cannot do without it. The most accurate assessment is therefore that prevention should be the priority and first line of defence — especially in LICs and for communicable disease — but the most effective overall strategy integrates prevention and cure within an equitable delivery model, tailored to a country's development level and disease profile. Prevention is more effective; it is not sufficient alone.

Global health risks such as pandemics, emerging diseases and antimicrobial resistance cross borders, which suggests they need international cooperation to manage. This essay evaluates that claim, arguing that cooperation is necessary but not sufficient — national action and other scales are also essential.

The case that international cooperation is essential. Because pathogens ignore borders, no country can be safe while a disease spreads elsewhere. The World Health Organization (WHO) provides global surveillance and early warning (declaring a PHEIC for COVID-19 in 2020 and for Ebola), coordinates guidance, and speeds shared research and genome sequencing. Cooperation is vital for equity: COVAX (WHO and GAVI) tried to distribute COVID-19 vaccines to LICs that could not afford them, and the Global Fund finances malaria, TB and HIV programmes worldwide. The 2014–16 West African Ebola epidemic (~11,300 deaths) was eventually contained by an international response led by the WHO and MSF, showing cooperation working. Managing antimicrobial resistance likewise needs global agreement on responsible antibiotic use. This strongly supports the statement.

The case that cooperation alone is not enough. However, the word 'only' makes the claim too strong. In practice, national governments do most of the actual managing — testing, lockdowns, vaccination roll-out, health systems and public-health messaging all happen at the national scale, and their effectiveness varies with development level and governance. Countries with strong systems (and even lower-income ones with good primary care, e.g. Cuba) manage outbreaks well, while fragile states struggle regardless of global help. Moreover, cooperation often fails or is unequal: 'vaccine nationalism' during COVID-19 saw HICs buy up supply, leaving LICs waiting, and the WHO cannot compel sovereign states or force honest reporting. So global mechanisms can be undermined by national self-interest.

The role of other players and scales. Management also depends on NGOs (MSF) reaching the excluded, pharmaceutical TNCs developing vaccines and drugs, and communities complying with measures (community health workers, hygiene behaviour). Effective management is therefore multi-scale, from the global to the local, not cooperation alone.

Conclusion. I partly agree: international cooperation is necessary for global health risks because surveillance, research-sharing and equitable vaccine access cannot be achieved by any single country, and pandemics by definition are global. But the claim that they can only be managed this way is too absolute — national governments deliver most management on the ground, cooperation is frequently weakened by self-interest (vaccine nationalism), and success depends on development level, delivery models and other players (NGOs, TNCs, communities). The most accurate view is that global health risks require international cooperation working together with strong national action across multiple scales — cooperation is essential, but not the whole answer.